Effect of nusinersen on respiratory function in patients with spinal muscular atrophy: an 18-month single-center prospective study - Scorecard - MDSpire
Clinical Scorecard: Impact of nusinersen on respiratory capabilities in individuals with spinal muscular atrophy: a prospective study over 18 months at a single center
At a Glance
Category
Detail
Condition
Spinal Muscular Atrophy (SMA)
Key Mechanisms
Nusinersen promotes the production of functional SMN protein by regulating SMN2 pre-mRNA splicing.
Target Population
Patients with spinal muscular atrophy, specifically Types II and III.
Care Setting
Pediatric department of a single center.
Key Highlights
67.5% of SMA patients had abnormal respiratory function at baseline.
Nusinersen improved respiratory function and active cough strength over 18 months.
Type II patients exhibited more severe respiratory impairment than Type III patients.
Effective cough increased from 39.1% to 56.5% after 18 months of treatment.
Nusinersen could not fully reverse the progression of restrictive ventilatory dysfunction.
Guideline-Based Recommendations
Diagnosis
Confirm SMN1 gene mutations via genetic testing.
Management
Administer nusinersen to improve respiratory function in SMA patients.
Monitoring & Follow-up
Evaluate respiratory function and active cough strength at baseline and during follow-up.
Risks
Ineffective cough and respiratory failure are common in SMA patients.
Patient & Prescribing Data
SMA patients aged from infancy to childhood, specifically Types II and III.
Nusinersen is the first FDA-approved drug for SMA, showing improvements in respiratory function.
Clinical Best Practices
Conduct regular assessments of respiratory function in SMA patients.
Utilize standardized remote video assessments for active cough strength.
A higher-dose nusinersen regimen for spinal muscular atrophy demonstrated statistically significant motor function improvement in treatment-naïve infants in the DEVOTE trial with a safety profile consistent with prior dosing.
